We are live on
!
Find out more
PCA
Private Capital Advisors Portfolio holdings
AUM
$1.15B
1-Year Est. Return
43.46%
This Fund
S&P 500
This Quarter
Est. Return
+11.1%
1 Year Est. Return
+43.46%
3 Year Est. Return
+131.91%
5 Year Est. Return
+229.29%
10 Year Est. Return
+757.55%
AUM
$292M
AUM Growth
+$16.8M
(+6.1%)
Cap. Flow
-$7.89M
Cap. Flow
% of AUM
-2.7%
Top 10 Holdings %
Top 10 Hldgs %
29.91%
Holding
120
New
8
Increased
27
Reduced
29
Closed
13
Avg Time Held
1.8
quarters
Top 10 Avg Time Held
1
quarter
Top 20 Avg Time Held
1.4
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SANGAMO THERAPEUTICS INC
SGMO
|
+$12.2M |
| 2 |
Arrowhead Research
ARWR
|
+$3.01M |
| 3 |
Biogen
BIIB
|
+$2.76M |
| 4 |
Gilead Sciences
GILD
|
+$1.62M |
| 5 |
Baidu
BIDU
|
+$1.52M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$6.53M |
| 2 |
Celldex Therapeutics
CLDX
|
+$6.14M |
| 3 |
YHOO
Yahoo Inc
YHOO
|
+$5.12M |
| 4 |
Alphabet (Google) Class C
GOOG
|
+$4.85M |
| 5 |
Noodles & Co
NDLS
|
+$2.64M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.95% |
| 2 | Energy | 16.91% |
| 3 | Communication Services | 13.82% |
| 4 | Industrials | 9.86% |
| 5 | Consumer Discretionary | 8.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
RH
RH
$2.19B
| $21.8M | 7.46% |
323,733
+15,400
| +5% | +$1.06M |
2013 Q2
2 quarters
|
|
|
2
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $14.7M | 5.04% |
+1,059,000
| New | +$12.2M |
2013 Q4
0 quarters
|
|
3
Apple
AAPL
$4.98T
| $9.4M | 3.22% |
469,280
+69,160
| +17% | +$1.31M |
2013 Q2
2 quarters
|
|
4
Enterprise Products Partners
EPD
$77.8B
| $6.67M | 2.28% |
201,210
+1,150
| +0.6% | +$35.8K |
2013 Q2
2 quarters
|
|
5
RTX Corp
RTX
$247B
| $6.45M | 2.21% |
90,112
-88
| -0.1% | -$6K |
2013 Q2
2 quarters
|
|
6
Blackstone
BX
$82.6B
| $5.89M | 2.02% |
190,461
-790
| -0.4% | -$21.5K |
2013 Q2
2 quarters
|
|
7
APA Corp
APA
$16.8B
| $5.78M | 1.98% |
67,238
+875
| +1% | +$77.9K |
2013 Q2
2 quarters
|
|
8
Pfizer
PFE
$162B
| $5.76M | 1.97% |
198,146
+4,954
| +3% | +$144K |
2013 Q2
2 quarters
|
|
9
McKesson
MCK
$112B
| $5.56M | 1.9% |
34,445
+325
| +1% | +$49.9K |
2013 Q2
2 quarters
|
|
10
Union Pacific
UNP
$168B
| $5.35M | 1.83% |
63,660
| – | – |
2013 Q2
2 quarters
|
|
11
IBM
IBM
$217B
| $5.11M | 1.75% |
28,475
-262
| -0.9% | -$45.2K |
2013 Q2
2 quarters
|
|
12
LyondellBasell Industries
LYB
$19.4B
| $5.1M | 1.75% |
63,495
+1,000
| +2% | +$76.6K |
2013 Q2
2 quarters
|
|
13
Liberty Media Corporation Series A Common Stock
FWONA
$21.4B
| $5.08M | 1.74% |
195,359
+3,631
| +2% | +$96.4K |
2013 Q2
2 quarters
|
|
|
CEO
14
DELISTED
CNOOC Limited
CEO
| $4.98M | 1.71% |
26,544
+37
| +0.1% | +$7.36K |
2013 Q2
2 quarters
|
|
15
EOG Resources
EOG
$80.3B
| $4.9M | 1.68% |
58,364
-4,600
| -7% | -$394K |
2013 Q2
2 quarters
|
|
16
Visa
V
$744B
| $4.9M | 1.68% |
87,980
-300
| -0.3% | -$15.1K |
2013 Q2
2 quarters
|
|
17
Plains All American Pipeline
PAA
$17.6B
| $4.9M | 1.68% |
94,570
-200
| -0.2% | -$10.2K |
2013 Q2
2 quarters
|
|
18
Eaton
ETN
$166B
| $4.84M | 1.66% |
63,590
+115
| +0.2% | +$8.18K |
2013 Q2
2 quarters
|
|
19
DELISTED
Paramount Global Class B
PARA
| $4.8M | 1.64% |
75,342
+115
| +0.2% | +$6.76K |
2013 Q2
2 quarters
|
|
20
Vodafone
VOD
$36B
| $4.61M | 1.58% |
115,102
-441
| -0.4% | -$16.6K |
2013 Q2
2 quarters
|
|
21
Citigroup
C
$209B
| $4.48M | 1.53% |
85,982
+1,325
| +2% | +$67.1K |
2013 Q2
2 quarters
|
|
22
Danaher
DHR
$157B
| $4.45M | 1.52% |
85,765
+543
| +0.6% | +$26.7K |
2013 Q2
2 quarters
|
|
23
ExxonMobil
XOM
$716B
| $4.38M | 1.5% |
43,247
| – | – |
2013 Q2
2 quarters
|
|
|
DTV
24
DELISTED
DIRECTV COM STK (DE)
DTV
| $4.34M | 1.49% |
62,845
+375
| +0.6% | +$24K |
2013 Q2
2 quarters
|
|
25
Liberty Global Class C
LBTYK
$2.87B
| $4.29M | 1.47% |
125,872
+1,681
| +1% | +$52.4K |
2013 Q2
2 quarters
|
|
Similar funds
WB
AIC
CFP
HT
AA
CIG
CIS
FWM
Private Capital Advisors's Q4 2013 Portfolio in Review
As of Q4 2013, Private Capital Advisors held 120 positions worth $292M, up 6.1% from $275M the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Private Capital Advisors's Q4 2013 filing shows 8 new, 27 increased, 29 reduced and 13 closed positions. Its largest new stake was SANGAMO THERAPEUTICS INC: 1,059,000 shares worth $14.7M. The largest sale was BioMarin Pharmaceuticals, an estimated $6.53M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, up from 20% a quarter earlier, followed by Energy and Communication Services.
- Private Capital Advisors's largest Q4 2013 buy was SANGAMO THERAPEUTICS INC: 1,059,000 shares worth $14.7M.
- Private Capital Advisors added most to Biogen in Q4 2013, an estimated $2.76M increase.
- Private Capital Advisors's biggest Q4 2013 reduction was Alphabet (Google) Class C, cutting an estimated $4.85M.
- Private Capital Advisors fully exited BioMarin Pharmaceuticals in Q4 2013, selling an estimated $6.53M.
- Private Capital Advisors's ten largest holdings make up 30% of its $292M portfolio in Q4 2013.
- Private Capital Advisors opened 8 new positions and closed 13 in Q4 2013.
- Private Capital Advisors's portfolio value rose 6.1% quarter-over-quarter to $292M.
Based on Private Capital Advisors's 13F filing for Q4 2013, filed 31 Jan 2014.